As filed with the Securities and Exchange Commission on May 29, 2019

Registration No. 333-209930

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Post-Effective Amendment No. 1

FORM F-6

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOR

AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS

Hutchison China MediTech Limited

(Exact name of issuer of deposited securities as specified in its charter)

Not Applicable

(Translation of issuer’s name into English)

Cayman Islands

(Jurisdiction of incorporation or organization of issuer)

Deutsche Bank Trust Company Americas

(Exact name of depositary as specified in its charter)

60 Wall Street

New York, New York 10005

(212) 250-9100

(Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

Puglisi & Associates

850 Library Avenue, Suite 204

Newark, Delaware 19711

(302) 738-6680

(Address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Deutsche Bank Trust Company Americas

Attention: ADR Department

60 Wall Street,

New York, New York 10005

(212) 250-9100

Francis Fitzherbert-Brockholes, Esq.

White & Case LLP

5 Old Broad Street
London EC2N 1DW
United Kingdom

+(44) 20 7532-1400

It is proposed that this filing become effective under Rule 466:

☐ immediately upon filing.

☒ on May 30, 2019 at 8:00 A.M. EST.

If a separate registration statement has been filed to register the deposited shares, check the following box: ☒

CALCULATION OF REGISTRATION FEE

Title of each class of Securities to be registered	Amount to be registered	Proposed maximum aggregate price per unit ⁽¹⁾	Proposed maximum aggregate offering price ⁽²⁾	Amount of registration fee ⁽³⁾
American Depositary Shares, each representing five (5) ordinary shares of Hutchison China MediTech Limited	N/A	N/A	N/A	N/A

¹	For the purpose of this table only the term "unit" is defined as one American Depositary Share.
²	Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of American Depositary Shares.
³	Previously paid.

This registration statement may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

PART I

INFORMATION REQUIRED IN PROSPECTUS

The prospectus consists of the proposed form of American Depositary Receipt (“Receipt”) included as Exhibits A and B to the form of Deposit Agreement filed as Exhibit (a) to the Registration Statement No. 333-209930 and is incorporated herein by reference.

Item 1. DESCRIPTION OF SECURITIES TO BE REGISTERED

Required Information				Location in Form of Receipt Filed Herewith as Prospectus

1.	Name of depositary and address of its principal executive office			Face of Receipt – introductory paragraph

2.	Title of Receipts and identity of deposited securities			Face of Receipt – top center

Terms of Deposit:

	(i)		The amount of deposited securities represented by one American Depositary Share (“ADS”)	Face of Receipt – upper right corner

	(ii)		The procedure for voting the deposited securities	Reverse of Receipt – Articles 14 and 15

	(iii)		The procedure for collecting and distributing dividends	Reverse of Receipt – Articles 13 and 14

	(iv)		The procedures for transmitting notices, reports and proxy soliciting material	Face of Receipt – Article 12; Reverse of Receipt – Articles 14 and 15

	(v)		The sale or exercise of rights	Reverse of Receipt – Articles 13 and 14

	(vi)		The deposit or sale of securities resulting from dividends, splits or plans of reorganization	Face of Receipt – Articles 3, 6 and 9; Reverse of Receipt – Articles 13 and 16

	(vii)		Amendment, extension or termination of the deposit arrangements	Reverse of Receipt – Articles 20 and 21 (no provision for extension)

	(viii)		The rights of holders of Receipts to inspect the books of the depositary and the list of holders of Receipts	Face of Receipt – Article 12

	(ix)		Restrictions upon the right to transfer or withdraw the underlying securities	Face of Receipt – Articles 2, 3, 4, 6, 8, 9 and 10; Reverse of Receipt – Article 22

	(x)	Limitation on the depositary’s liability		Face of Receipt – Articles 6 and 10; Reverse of Receipt – Articles 15, 16, 17 and 18

3.	Fees and charges that a holder of Receipts may have to pay, either directly or indirectly			Face of Receipt – Article 9

Item 2. AVAILABLE INFORMATION

Hutchison China MediTech Limited (the “Company”) is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, files certain reports with, and furnishes certain reports to, the Commission. These reports can be retrieved from the Commission’s internet website (www.sec.gov) and can be inspected and copied at the public reference facilities maintained by the Commission at 100 F Street, N.E., Washington D.C. 20549.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 3. EXHIBITS

	(a)(1)	Deposit Agreement, dated March 16, 2016, among the Company, Deutsche Bank Trust Company Americas, as depositary (the “Depositary”), and all holders and beneficial owners from time to time of ADSs issued thereunder (“Deposit Agreement”). — Previously filed as an exhibit to Registration Statement No. 333-209930 and incorporated herein by reference

	(a)(2)	Form of Amendment No. 1 to Deposit Agreement. — Filed herewith as Exhibit (a)(2).

	(b)	Any other agreement to which the Depositary is a party relating to the issuance of the ADSs registered hereunder or the custody of the deposited securities represented thereby. — Not applicable.

	(c)	Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. — Not applicable.

	(d)	Opinion of White & Case LLP, counsel to the Depositary, as to the legality of the securities to be registered. — Previously filed as an exhibit to Registration Statement No. 333-209930.

	(e)	Certification under Rule 466. — Filed herewith as Exhibit (e).

	(f)	Powers of attorney for certain officers and directors of the Company. — Set forth on the signature pages hereto.

Item 4. UNDERTAKINGS

	(a)	The Depositary hereby undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of the ADR, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities; and (2) made generally available to the holders of the underlying securities by the issuer.

	(b)	If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADR thirty (30) days before any change in the fee schedule.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-effective Amendment No. 1 to the registration statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on May 29, 2019.

Legal entity created by the form of Deposit Agreement for the issuance of Receipts for ordinary shares, par value US$1.00 per share of Hutchison China MediTech Limited.
Deutsche Bank Trust Company Americas, as Depositary


By:	/s/ Beverly George Prowell
	Name:	Beverly George Prowell
	Title:	Vice President


By:	/s/ Rohan Bridgett
	Name:	Rohan Bridgett
	Title:	Vice President

Pursuant to the requirements of the Securities Act of 1933, as amended, Hutchison China MediTech Limited certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this registration statement on Post-effective Amendment No. 1 to Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Hong Kong, Special Administrative Region of the People’s Republic of China on May 29, 2019.

Hutchison China MediTech Limited


By:	/s/ Christian Hogg
	Name:	Christian Hogg
	Title:	Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Post-effective Amendment No. 1 to Form F-6 has been signed by the following persons in the capacities indicated on May 29, 2019.

Signature		Title

*		Executive Director and Chairman
Name: Simon To


*		Executive Director and Chief Executive Officer
Name: Christian Hogg


*		Executive Director and Chief Financial Officer
Name: Johnny Cheng


*		Non-executive Director and Company Secretary
Name: Edith Shih

*By:	/s/ Christian Hogg
	Name:	Christian Hogg
	Title:	Attorney-in-Fact

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Mr. Simon To and Mr. Christian Hogg, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this registration statement and any and all related registration statements pursuant to Rule 462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Under the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons on May 29, 2019, in the capacities indicated.

Signature		Title

/s/ Wei-guo Su		Executive Director and Chief Scientific Officer
Name: Wei-guo Su

/s/ Dan Eldar		Non-executive Director
Name: Dan Eldar

/s/ Paul Rutherford Carter		Senior Independent Non-executive Director
Name: Paul Rutherford Carter

/s/ Karen Jean Ferrante		Independent Non-executive Director
Name: Karen Jean Ferrante

/s/ Graeme Allan Jack		Independent Non-executive Director
Name: Graeme Allan Jack

/s/ Mok Shu Kam Tony		Independent Non-executive Director
Name: Mok Shu Kam Tony

SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Hutchison China MediTech Limited, has signed this Post-effective Amendment No. 1 to the registration statement in Newark, Delaware, United States of America on May 29, 2019.

	Puglisi & Associates


	By:	/s/ Donald J. Puglisi
		Name: Donald J. Puglisi
		Title: Service of Process Officer

Index to Exhibits

Exhibit	Document
(a)(2)	Form of Amendment No. 1 to the Deposit Agreement
(e)	Rule 466 certification